This Study is to Describe and Evaluate Patients in Finland Treated With Tofacitinib for the Treatment of Ulcerative Colitis Using Real World Data.

Pfizer

Status: Completed

Conditions: Ulcerative Colitis

Study type: Observational

Funder types: Industry

Identifiers

NCT05082428

FinTofUC (Other Identifier)

A3921390

Details and patient eligibility

About

The aim of this study is to describe and evaluate clinical outcomes, treatment lines, and to identify the key characteristics of the patients treated with tofacitinib.

Enrollment: 252 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Xeljanz (tofacitinib) usage for ulcerative colitis
• Diagnosis of ulcerative colitis (ICD-10: K51.0, K51.1, K51.2, K51.3, K51.5, K51.8, K51.9) between January 2010 and December 2021 (incident or prevalent).

Exclusion criteria

• Age < 18 years at the start of tofacitinib use
• Use of tofacitinib before reimbursement (1.3.2019)
• < 8 weeks of treatment with tofacitinib at the start of data mining
• History of panproctocolectomy, IPAA or ileostomy.

Trial design

252 participants in 1 patient group

Patients treated with Tofacitinib

Description:

Patients treated with tofacitinib for ulcerative colitis in Finland.